Number of Clinical Trials 2008
Explore the number of clinical trials conducted in various countries; critical for medical research and innovation.
Newer data is available: Number of Clinical Trials by country 2024 →
Where does your country rank? Pick it to see its position.
Related Health statistics
More ↓Interactive Map
Complete Data Rankings
- #1
United States
- #2
Germany
- #3
Canada
- #4
France
- #5
United Kingdom
- #6
Japan
- #7
Italy
- #8
Denmark
- #9
Brazil
- #10
Netherlands
Analysis: These countries represent the highest values in this dataset, showcasing significant scale and impact on global statistics.
- #102
Slovenia
- #101
Sierra Leone
- #100
Qatar
- #99
North Macedonia
- #98
Nicaragua
- #97
Mozambique
- #96
Mali
- #95
Jordan
- #94
Iceland
- #93
Gambia
Context: These countries or territories have the lowest values, often due to geographic size, administrative status, or specific characteristics.
Insights by country
Congo, Democratic Republic of the
Congo, Democratic Republic of the ranked #67 globally with a total of 2 clinical trials in 2008. This figure is notably lower than many of its African neighbors, reflecting challenges in research infrastructure and funding. The limited number of clinical trials can be attributed to ongoing political instability and a lack of investment in healthcare research, which hampers the country's ability to attract international research collaborations.
Netherlands
In 2008, the Netherlands ranked #10 globally with a total of 115 clinical trials. This figure positions the country above the global average, reflecting its robust research infrastructure compared to many neighbors. The Netherlands benefits from a strong emphasis on innovation in healthcare, supported by government policies that encourage clinical research and collaboration between academic institutions and the pharmaceutical industry.
Croatia
In 2008, Croatia had a global rank of #87 out of 102 countries with a total of 1 clinical trial. This figure is significantly lower than the European average, reflecting the challenges faced by the country in attracting research investment. Factors contributing to this low number include a relatively small population and limited funding for biomedical research, which hinder the development of a robust clinical trial infrastructure.
Indonesia
In 2008, Indonesia ranked #51 globally with a total of 5 clinical trials. This figure is notably lower than the regional average, reflecting challenges in research infrastructure compared to its Southeast Asian neighbors. Key drivers behind this statistic include limited funding for medical research and a complex regulatory environment that can hinder trial initiation.
Mexico
In 2008, Mexico ranked #28 globally with a total of 34 clinical trials. This figure is notable given that it positions Mexico above many of its regional peers in Latin America, reflecting a growing interest in clinical research. Contributing factors include Mexico's strategic geographic location, a diverse population that facilitates varied clinical studies, and an increasing investment in healthcare infrastructure aimed at boosting research capabilities.
Japan
In 2008, Japan ranked #6 globally with a total of 163 clinical trials. This figure is significant when compared to the global average, highlighting Japan's robust position in clinical research. Key drivers include Japan's advanced healthcare infrastructure and its commitment to innovation in medical technology, bolstered by a strong regulatory framework that encourages clinical studies.
Benin
In 2008, Benin ranked #88 globally with just 1 clinical trial. This low number reflects a significant gap in clinical research activity compared to regional leaders, highlighting the challenges faced by many West African nations in advancing medical research. Limited funding, inadequate healthcare infrastructure, and a lack of local research institutions hinder the country's ability to attract and conduct clinical trials.
Nicaragua
Nicaragua ranked #96 globally with a total of 1 clinical trial in 2008. This figure is significantly lower than many of its Central American neighbors, reflecting a regional trend where countries like Costa Rica and Panama have more robust clinical research infrastructures. The limited number of clinical trials in Nicaragua can be attributed to factors such as a smaller healthcare research community, economic constraints, and a lack of investment in medical research initiatives.
Fiji
In 2008, Fiji ranked #90 globally with a total of 1 clinical trial. This figure is significantly lower than many neighboring countries, indicating limited clinical research activity in the region. Factors contributing to this low number include Fiji's smaller population and economic constraints, which can hinder investment in extensive clinical research initiatives.
Bangladesh
In 2008, Bangladesh ranked #37 globally with a total of 11 clinical trials. This figure is modest compared to leading countries in clinical research, reflecting a growing but still nascent infrastructure in the sector. The relatively low number of trials can be attributed to challenges such as limited funding for research, a developing healthcare system, and regulatory hurdles that impact the clinical research landscape.
Austria
In 2008, Austria ranked #22 globally with a total of 56 clinical trials. This figure is notable, considering that it reflects a robust research environment compared to some neighboring countries in Central Europe. The country's strong healthcare infrastructure and a focus on medical research, supported by government policies and a skilled workforce, contribute significantly to its clinical trial activity.
Dominican Republic
In 2008, the Dominican Republic ranked #54 globally with a total of 4 clinical trials. This figure is relatively low compared to other countries in the region, reflecting a growing but still limited clinical research environment. Key drivers for this statistic include the country's developing healthcare infrastructure and a focus on tourism over extensive medical research investment.
Belarus
In 2008, Belarus ranked #85 globally with only 1 clinical trial recorded. This figure is notably low compared to neighboring countries, reflecting a lack of robust clinical research infrastructure in the region. Factors contributing to this statistic include Belarus's centralized healthcare system and limited investment in biomedical research, which restricts opportunities for clinical trial development.
Kenya
In 2008, Kenya ranked #45 globally with a total of 8 clinical trials. This figure is notably lower than that of neighboring Uganda, which had a more robust clinical research framework at the time. The limited number of trials in Kenya can be attributed to factors such as insufficient funding for research initiatives and a relatively nascent regulatory environment for clinical studies.
Israel
In 2008, Israel ranked #14 globally with a total of 91 clinical trials. This figure is notable when compared to neighboring countries, which often have fewer trials due to varying levels of investment in research and development. Israel's robust biotechnology sector, combined with a strong emphasis on innovation and collaboration between academia and industry, significantly contributes to its high number of clinical trials.
China, Hong Kong SAR
In 2008, China, Hong Kong SAR ranked #39 globally with a total of 10 clinical trials. This figure is relatively low compared to leading regions, reflecting a growing but still developing research environment. Factors such as a robust healthcare system, increasing investment in biomedical research, and a strategic focus on innovation have begun to enhance the clinical trial landscape in Hong Kong SAR.
Tunisia
Tunisia ranked #79 globally with 2 clinical trials in 2008. This number is notably lower than many of its regional peers, indicating limited engagement in clinical research activities. Factors contributing to this statistic include a relatively small biomedical research sector and challenges in attracting foreign investment in clinical studies.
Analysis & Context
The United States led the world in the Number of Clinical Trials in 2008, conducting 3,556 trials, while globally, the number ranged from 1 to 3,556. The average number of clinical trials conducted worldwide was 68.50, with a median of 5.00, indicating a significant disparity in clinical research activity across countries.
Concentration of Clinical Trials in Developed Nations
The data shows a clear concentration of clinical trials in developed countries, with the United States, Germany, and Canada occupying the top three spots. This pattern reflects the strong healthcare infrastructure, substantial funding for medical research, and a robust regulatory environment in these nations. For example, the United States conducted over ten times more trials than Germany, which ranked second with 348 trials. This disparity highlights the U.S.'s dominant position in the global pharmaceutical and biotechnology industries, driven by substantial public and private investment in research and development.
Other European countries such as France and the United Kingdom also feature prominently, with 238 and 200 trials respectively. These countries benefit from strong academic institutions and collaborations between universities and industry, which foster a conducive environment for clinical research. The presence of established regulatory frameworks and supportive government policies further enhances their capacity to conduct a high number of trials.
Emerging Markets and Limited Clinical Trials
In contrast, many emerging markets and developing countries conducted minimal clinical trials in 2008. Nations like Nicaragua, Uruguay, and El Salvador each reported just 1 trial. This limited activity can be attributed to several factors, including inadequate infrastructure, lower levels of investment in healthcare research, and regulatory hurdles. Additionally, these countries may prioritize other pressing public health needs over clinical research.
However, the presence of Brazil in the top ten, with 133 trials, signals a growing capacity for clinical research in some emerging economies. Brazil's performance can be linked to its expanding pharmaceutical sector and efforts to integrate into the global research community, demonstrating the potential for growth in other similar markets.
Year-over-Year Changes and Significant Increases
The year-over-year data reveals that some countries made notable progress in increasing their number of clinical trials. The United States saw the largest absolute increase, adding 602 trials, a rise of 20.4%. This growth is indicative of the U.S.'s continued leadership in medical innovation and the expansion of its research capabilities.
France and Canada also experienced significant increases, with 81 (a 51.6% increase) and 72 (a 29.3% increase) additional trials, respectively. These increases may be attributed to enhanced funding for research initiatives and strategic partnerships with industry players. Moreover, Japan witnessed a substantial rise of 68 trials, reflecting its commitment to advancing its clinical research landscape, which saw a 71.6% growth.
Challenges in Maintaining Clinical Trial Numbers
On the other end of the spectrum, some countries faced declines in their clinical trial numbers. Argentina experienced a reduction of 4 trials, a drop of 22.2%. Similarly, Uganda and Mali saw decreases of 3 trials each, with Mali experiencing a drastic 75.0% decline. These reductions could be linked to shifts in funding priorities, regulatory challenges, or geopolitical issues that hinder the ability to conduct consistent research activities.
Overall, the Number of Clinical Trials in 2008 highlights the stark contrasts between developed and developing nations in terms of research capacity. While certain countries demonstrate remarkable growth and leadership in clinical research, others face significant barriers that limit their participation in global medical advancements. Understanding these dynamics is crucial for fostering a more equitable distribution of clinical research efforts worldwide.
Frequently Asked Questions About Number of Clinical Trials in 2008
Which country had the highest number of clinical trials in 2008?
The United States had the highest number of clinical trials in 2008, with a total of 3,556 trials.
What was the average number of clinical trials conducted by countries in 2008?
The average number of clinical trials conducted by countries in 2008 was 68.5.
Which country had the lowest number of clinical trials in 2008?
Nicaragua had the lowest number of clinical trials in 2008, with only 1 trial conducted.
What was the median number of clinical trials conducted by countries in 2008?
The median number of clinical trials conducted by countries in 2008 was 5.
How many countries were included in the dataset for clinical trials in 2008?
The dataset for clinical trials in 2008 included 102 countries.
Which countries were in the top 10 for the number of clinical trials in 2008?
The top 10 countries for the number of clinical trials in 2008 were the United States, Germany, Canada, France, United Kingdom, Japan, Italy, Denmark, Brazil, and Netherlands.
Data Source
Number of clinical trials | ClinicalTrials.gov via Our World in Data
Data produced by ClinicalTrials.gov, compiled and published by Our World in Data as "Number of clinical trials".
Visit Data SourceCite this page
Geo Factbook. (n.d.). Number of Clinical Trials by Country, 2008. Retrieved November 16, 2026, from https://geofactbook.com/fact/number-of-clinical-trials/2008
The figures on this page come from Number of clinical trials | ClinicalTrials.gov via Our World in Data. For academic work, cite the original source as well.
›Embed this ranking on your site
Free to embed with attribution. Shows the top 10 countries and links back to the full ranking.